继发性性腺功能减退症与睾酮替代治疗对心血管事件的影响
本研究为回顾性队列研究,纳入408例非功能性垂体腺瘤或泌乳素瘤男性患者,随访中位8.1年。结果显示睾酮替代治疗未显著增加主要不良心血管事件风险,而未治疗的继发性性腺功能减退症与死亡率升高相关。
要点
- 睾酮替代治疗未增加垂体疾病相关继发性性腺功能减退症患者的主要不良心血管事件风险。
- 未治疗的继发性性腺功能减退症患者死亡率高于治疗组和无该症组。
- 腺瘤大小、其他垂体激素缺乏及睾酮水平未影响主要不良心血管事件结局。
核心结论
- 睾酮替代治疗似乎不增加垂体疾病相关继发性性腺功能减退症患者的主要不良心血管事件风险。
- 未治疗的继发性性腺功能减退症与死亡率升高相关,但该组患者年龄更大且合并症更多。
研究设计与样本
- 回顾性队列研究,纳入408例非功能性垂体腺瘤和泌乳素瘤男性患者,随访中位8.1年(四分位距3.3-14.1)。
主要发现
- 150例(36.7%)无继发性性腺功能减退症,214例(52.5%)接受睾酮替代治疗且治疗充分,44例(10.8%)未治疗。
- 多变量logistic回归分析显示组间主要不良心血管事件无显著差异。
- 主要不良心血管事件结局不受腺瘤大小、其他垂体激素缺乏或睾酮水平影响。
- 未治疗继发性性腺功能减退症组死亡率高于睾酮替代治疗组和无该症组。
临床怎么用
- 对垂体疾病相关的继发性性腺功能减退症男性患者,睾酮替代治疗未显示增加主要不良心血管事件风险。
- 需关注未治疗的继发性性腺功能减退症患者死亡风险升高,但应考虑其年龄和合并症的影响。
局限性
- 回顾性研究设计。
- 未治疗组患者年龄更大且合并症更多,可能影响死亡率比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The safety of testosterone replacement therapy (TRT) has generated some controversy during recent years. While untreated hypogonadism leads to diminished sexual characteristics, muscle weakness and osteoporosis, the cardiovascular safety of TRT has been vigorously debated. TRT remains the standard of care for those with secondary hypogonadism (SHG) due to structural pituitary disease, but long-term cardiovascular safety in this population remains unclear. METHODS: We conducted a retrospective cohort study to investigate occurrence of major adverse cardiovascular events (MACE) in male patients with nonfunctioning pituitary adenomas and prolactinomas, with and without SHG. Demographic data, TRT treatment, stroke, myocardial infarction, and mortality data were retrieved from chart review as well as provincial cardiac and stroke registries. RESULTS: There were 408 patients followed for a median 8.1 years (interquartile range 3.3-14.1); 150 (36.7%) did not have SHG, whereas 214 (52.5%) had SHG adequately treated with TRT and 44 (10.8%) had SHG that was untreated. Multivariable logistic regression analysis demonstrated no significant difference in MACE between groups. MACE outcomes were not impacted by size of adenoma, presence of other pituitary hormonal deficits, or testosterone levels. There was increased risk of mortality in untreated SHG compared to both TRT-treated SHG and those without SHG. CONCLUSION: TRT does not appear to increase risk of MACE in those with SHG related to pituitary disorders. Untreated SHG appears to convey increased risk of mortality though these patients were older and more comorbid.
引用
- Munro V, Law J, Matheson K, et al. Secondary Hypogonadism and Effects of Testosterone Replacement Therapy on Cardiovascular Events. J Clin Endocrinol Metab. 2026. PMID: 41252267. doi:10.1210/clinem/dgaf631
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。